流感最新消息第549号

GLOBAL INFLUENZA SURVEILLANCE AND RESPONSE SYSTEM (GISRS) RSV SARS-CoV-2 Influenza Co-circulation SUMMARY (Based on data reported to WHO for week 41, ending 12 October 2025) Globally, influenza and SARS-CoV-2 activity remained low in week 41. At these low levels of circulation, SARS-CoV-2 predominated with percent positivityincreasing gradually in recent weeks. SARS-CoV-2 predominated in the temperate and subtropical areas of the northern hemisphere, whereas influenza waspredominant in tropical areas, with influenza positivity above 10%, and in the temperate and subtropical areas of the southern hemisphere where influenzapercent positivity was below 10%. [Figures 1a, 1b, 1c and 1d] qInfluenza Globally, influenza activity remained low, with influenza A viruses continuing to predominate. [Figure 2] In the northern hemisphere temperate regions, influenza activity remained low and stable. Influenza percent positivity was elevated in CentralAmerica and the Caribbean, Northern Africa, and Northern Europe, with levels over 30% seen in Western and Middle Africa, Western, Southern andSouth-East Asia. An increase in activity was observed in countries in Central America and the Caribbean, Western and Middle Africa, Western,Southern and South-East Asia. [Figures 3 and 4] In the southern hemisphere, influenza activity remained low and stable in most countries with elevated positivity (>10%) seen in single countries inTemperate South America, Eastern Africa and South-East Asia and percent positivity over 30% was seen in a single country in South-East Asia. Noincreasing trends in activity were seen in the Southern Hemisphere. [Figures 3 and 4] In the transmission zones with elevated positivity, influenza A(H1N1)pdm09 predominated in Central America and the Caribbean, Northern andMiddle Africa whereas influenza A(H3N2) was the predominant circulating subtype in Eastern Africa, Western, Southern and South-East Asia andTemperate South America. Influenza A(H1N1)pdm09 and influenza A(H3N2) were codominant in Western Africa and Northern Europe. [Figures 5 and 6] qSARS-CoV-2 Globally, SARS-CoV-2 positivity increased but remained at low levels, with some countries reporting elevated positivity (>10%) in Central Americaand the Caribbean, Tropical South America, South-West and Eastern Europe, and Eastern Asia. Small increases in activity were reported in singlecountries in Central America and the Caribbean and Tropical South America. [Figures 7 and 8] qRespiratory Syncytial Virus (RSV)RSV percent positivity remained elevated in some countries in Central America and the Caribbean, Tropical and Temperate South America, with levels of over 30% in one country in Central America and the Caribbean. RSV positivity remained stable across most countries, with increases inactivity seen in two countries in Central America and the Caribbean. [Figures 9 and 10] Co-circulation of influenza and SARS-CoV-2 1a) Weekly numbers of influenza and SARS-CoV-2 virus specimens tested and percent positivity at the global level(last 12 months) 1c) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Tropical areas 1b) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Northern hemispheretemperate and subtropical areas 1d) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Southern hemispheretemperate and subtropical areas Influenza 2) Weekly numbers of influenza virus positive specimens by type and subtype and percent positivity at the globallevel (last 12 months) 4) Change in proportions of specimens that testedpositive for influenza (year-week:2025-41) 3) Proportions of specimens that tested positive forinfluenza (year-week:2025-41) 6) Weekly distribution of influenza virus types andsubtypes by geographic zone (last 12 months) 5) Proportions of influenza virus types and subtypes byinfluenza transmission zones (year-week:2025-41) SARS-CoV-2 8) Change in proportions of specimens that testedpositive for SARS-CoV-2 (year-week:2025-41) 7) Proportions of specimens that tested positive forSARS-CoV-2 (year-week:2025-41) Respiratory syncytial virus 10) Change in proportions of specimens that testedpositive for RSV (year-week:2025-41) 9) Proportions of specimens that tested positive for RSV(year-week:2025-41) Additional information Data and methods The data presented in this report originates from virologic surveillance conducted by countries, areas, and territories (CATs) andsubmitted to WHO FluNet through participation or collaboration with the Global Influenza Surveillance and Response System(GISRS). These CATs employ diverse methodologies to monitor respiratory virus activity, which may result in variations betweenthis report and other surveillance summaries published elsewhere. This report includes virologic data from bothsentinel surveillance and other systematically conducted surveillance. Dueto differences in